The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers
Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis an...
Gespeichert in:
| Veröffentlicht in: | International journal of oncology 2014-05, Vol.44 (5), p.1461-1469 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1469 |
|---|---|
| container_issue | 5 |
| container_start_page | 1461 |
| container_title | International journal of oncology |
| container_volume | 44 |
| creator | OJI, YUSUKE TATSUMI, NAOYA FUKUDA, MARI NAKATSUKA, SHIN-ICHI AOYAGI, SAYAKA HIRATA, ERIKA NANCHI, ISAMU FUJIKI, FUMIHIRO NAKAJIMA, HIROKO YAMAMOTO, YUMIKO SHIBATA, SYOHEI NAKAMURA, MICHIYO HASEGAWA, KANA TAKAGI, SAYAKA FUKUDA, IKUYO HOSHIKAWA, TOMOKO MURAKAMI, YUI MORI, MASAHIDE INOUE, MASAYOSHI NAKA, TETSUJI TOMONAGA, TAKESHI SHIMIZU, YOSHIFUMI NAKAGAWA, MASASHI HASEGAWA, JUNICHI NEZU, RIICHIRO INOHARA, HIDENORI IZUMOTO, SHUICHI NONOMURA, NORIO YOSHIMINE, TOSHIKI OKUMURA, MEINOSHIN MORII, EIICHI MAEDA, HAJIME NISHIDA, SUMIYUKI HOSEN, NAOKI TSUBOI, AKIHIRO OKA, YOSHIHIRO SUGIYAMA, HARUO |
| description | Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin's lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786-794 aa) and EF292 (eEF2 292-300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A*24:02- and an HLA-A*02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers. |
| doi_str_mv | 10.3892/ijo.2014.2318 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4027928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A412556702</galeid><sourcerecordid>A412556702</sourcerecordid><originalsourceid>FETCH-LOGICAL-c611t-2dd678865c964a15873c77c5eb48e8778eafa2bd03146087700aa50c07fa789d3</originalsourceid><addsrcrecordid>eNptkk1rGzEQhpfS0ny0x16LoNCe1tXXrrSXQghJWgj0kp7FWDtry-xKrqQ1zb-vjFNjQ9FBw8wzL5rRW1UfGF0I3fGvbhMWnDK54ILpV9UlUx2rueTidYkp6-pWiu6iukppQylvGsreVhdcNrprG35Z5ac1khzBpxGyC57gGPzqEA5gc4gE7-45cYkA8WGHI8nzFGINKQXrIGNPwGe3Qk9KNeKfbcSUStZ5soPowpxIft5iImEgFrzFmN5VbwYYE75_ua-rX_d3T7ff68efDz9ubx5r2zKWa973rdK6bWzXSmCNVsIqZRtcSo1aKY0wAF_2VDDZ0pKgFKChlqoBlO56cV19O-hu5-WEvUVfJh3NNroJ4rMJ4Mx5xbu1WYWdkZSrjusi8OlFIIbfM6ZsNmGOvrzZsE5wwTuhT6gVjGicH0IRs5NL1txIVnbeKsoLtfgPVU6Pk7PB4-BK_qzh80nDGmHM6xTGef836RysD6CNIaWIw3FCRs3eJKaYxOxNYvYmKfzH07Uc6X-uKMCXA5C24HvXh3RkilItZU2buuycib9yScTL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1932329388</pqid></control><display><type>article</type><title>The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers</title><source>Spandidos Publications Journals</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>OJI, YUSUKE ; TATSUMI, NAOYA ; FUKUDA, MARI ; NAKATSUKA, SHIN-ICHI ; AOYAGI, SAYAKA ; HIRATA, ERIKA ; NANCHI, ISAMU ; FUJIKI, FUMIHIRO ; NAKAJIMA, HIROKO ; YAMAMOTO, YUMIKO ; SHIBATA, SYOHEI ; NAKAMURA, MICHIYO ; HASEGAWA, KANA ; TAKAGI, SAYAKA ; FUKUDA, IKUYO ; HOSHIKAWA, TOMOKO ; MURAKAMI, YUI ; MORI, MASAHIDE ; INOUE, MASAYOSHI ; NAKA, TETSUJI ; TOMONAGA, TAKESHI ; SHIMIZU, YOSHIFUMI ; NAKAGAWA, MASASHI ; HASEGAWA, JUNICHI ; NEZU, RIICHIRO ; INOHARA, HIDENORI ; IZUMOTO, SHUICHI ; NONOMURA, NORIO ; YOSHIMINE, TOSHIKI ; OKUMURA, MEINOSHIN ; MORII, EIICHI ; MAEDA, HAJIME ; NISHIDA, SUMIYUKI ; HOSEN, NAOKI ; TSUBOI, AKIHIRO ; OKA, YOSHIHIRO ; SUGIYAMA, HARUO</creator><creatorcontrib>OJI, YUSUKE ; TATSUMI, NAOYA ; FUKUDA, MARI ; NAKATSUKA, SHIN-ICHI ; AOYAGI, SAYAKA ; HIRATA, ERIKA ; NANCHI, ISAMU ; FUJIKI, FUMIHIRO ; NAKAJIMA, HIROKO ; YAMAMOTO, YUMIKO ; SHIBATA, SYOHEI ; NAKAMURA, MICHIYO ; HASEGAWA, KANA ; TAKAGI, SAYAKA ; FUKUDA, IKUYO ; HOSHIKAWA, TOMOKO ; MURAKAMI, YUI ; MORI, MASAHIDE ; INOUE, MASAYOSHI ; NAKA, TETSUJI ; TOMONAGA, TAKESHI ; SHIMIZU, YOSHIFUMI ; NAKAGAWA, MASASHI ; HASEGAWA, JUNICHI ; NEZU, RIICHIRO ; INOHARA, HIDENORI ; IZUMOTO, SHUICHI ; NONOMURA, NORIO ; YOSHIMINE, TOSHIKI ; OKUMURA, MEINOSHIN ; MORII, EIICHI ; MAEDA, HAJIME ; NISHIDA, SUMIYUKI ; HOSEN, NAOKI ; TSUBOI, AKIHIRO ; OKA, YOSHIHIRO ; SUGIYAMA, HARUO</creatorcontrib><description>Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin's lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786-794 aa) and EF292 (eEF2 292-300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A*24:02- and an HLA-A*02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers.</description><identifier>ISSN: 1019-6439</identifier><identifier>EISSN: 1791-2423</identifier><identifier>DOI: 10.3892/ijo.2014.2318</identifier><identifier>PMID: 24589652</identifier><language>eng</language><publisher>Greece: D.A. Spandidos</publisher><subject>Analysis ; Antigens ; Antigens, Neoplasm - genetics ; Antigens, Neoplasm - metabolism ; autoantibody ; Breast cancer ; Cancer ; cancer immunotherapy ; Cancer therapies ; Cell cycle ; Cell growth ; Cell Line, Tumor ; cytotoxic T lymphocyte ; Elongation Factor 2 Kinase - genetics ; Elongation Factor 2 Kinase - metabolism ; Esophagus ; eukaryotic elongation factor 2 ; Gastric cancer ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Genetic aspects ; Health aspects ; Humans ; Immunoglobulin G - immunology ; Immunoglobulins ; Immunotherapy ; Leukemia ; Lung cancer ; Lymphoma ; Mass spectrometry ; MCF-7 Cells ; Neoplasms - genetics ; Neoplasms - immunology ; Neoplasms - pathology ; Oncology, Experimental ; Pancreatic cancer ; Physiological aspects ; Prostate ; Proteins ; Scientific imaging ; Sequence Analysis, DNA ; T-Lymphocytes, Cytotoxic - immunology ; tumor associated antigen</subject><ispartof>International journal of oncology, 2014-05, Vol.44 (5), p.1461-1469</ispartof><rights>Copyright © 2014, Spandidos Publications</rights><rights>COPYRIGHT 2014 Spandidos Publications</rights><rights>Copyright Spandidos Publications UK Ltd. 2014</rights><rights>Copyright © 2014, Spandidos Publications 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c611t-2dd678865c964a15873c77c5eb48e8778eafa2bd03146087700aa50c07fa789d3</citedby><cites>FETCH-LOGICAL-c611t-2dd678865c964a15873c77c5eb48e8778eafa2bd03146087700aa50c07fa789d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,5571,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24589652$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OJI, YUSUKE</creatorcontrib><creatorcontrib>TATSUMI, NAOYA</creatorcontrib><creatorcontrib>FUKUDA, MARI</creatorcontrib><creatorcontrib>NAKATSUKA, SHIN-ICHI</creatorcontrib><creatorcontrib>AOYAGI, SAYAKA</creatorcontrib><creatorcontrib>HIRATA, ERIKA</creatorcontrib><creatorcontrib>NANCHI, ISAMU</creatorcontrib><creatorcontrib>FUJIKI, FUMIHIRO</creatorcontrib><creatorcontrib>NAKAJIMA, HIROKO</creatorcontrib><creatorcontrib>YAMAMOTO, YUMIKO</creatorcontrib><creatorcontrib>SHIBATA, SYOHEI</creatorcontrib><creatorcontrib>NAKAMURA, MICHIYO</creatorcontrib><creatorcontrib>HASEGAWA, KANA</creatorcontrib><creatorcontrib>TAKAGI, SAYAKA</creatorcontrib><creatorcontrib>FUKUDA, IKUYO</creatorcontrib><creatorcontrib>HOSHIKAWA, TOMOKO</creatorcontrib><creatorcontrib>MURAKAMI, YUI</creatorcontrib><creatorcontrib>MORI, MASAHIDE</creatorcontrib><creatorcontrib>INOUE, MASAYOSHI</creatorcontrib><creatorcontrib>NAKA, TETSUJI</creatorcontrib><creatorcontrib>TOMONAGA, TAKESHI</creatorcontrib><creatorcontrib>SHIMIZU, YOSHIFUMI</creatorcontrib><creatorcontrib>NAKAGAWA, MASASHI</creatorcontrib><creatorcontrib>HASEGAWA, JUNICHI</creatorcontrib><creatorcontrib>NEZU, RIICHIRO</creatorcontrib><creatorcontrib>INOHARA, HIDENORI</creatorcontrib><creatorcontrib>IZUMOTO, SHUICHI</creatorcontrib><creatorcontrib>NONOMURA, NORIO</creatorcontrib><creatorcontrib>YOSHIMINE, TOSHIKI</creatorcontrib><creatorcontrib>OKUMURA, MEINOSHIN</creatorcontrib><creatorcontrib>MORII, EIICHI</creatorcontrib><creatorcontrib>MAEDA, HAJIME</creatorcontrib><creatorcontrib>NISHIDA, SUMIYUKI</creatorcontrib><creatorcontrib>HOSEN, NAOKI</creatorcontrib><creatorcontrib>TSUBOI, AKIHIRO</creatorcontrib><creatorcontrib>OKA, YOSHIHIRO</creatorcontrib><creatorcontrib>SUGIYAMA, HARUO</creatorcontrib><title>The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers</title><title>International journal of oncology</title><addtitle>Int J Oncol</addtitle><description>Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin's lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786-794 aa) and EF292 (eEF2 292-300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A*24:02- and an HLA-A*02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers.</description><subject>Analysis</subject><subject>Antigens</subject><subject>Antigens, Neoplasm - genetics</subject><subject>Antigens, Neoplasm - metabolism</subject><subject>autoantibody</subject><subject>Breast cancer</subject><subject>Cancer</subject><subject>cancer immunotherapy</subject><subject>Cancer therapies</subject><subject>Cell cycle</subject><subject>Cell growth</subject><subject>Cell Line, Tumor</subject><subject>cytotoxic T lymphocyte</subject><subject>Elongation Factor 2 Kinase - genetics</subject><subject>Elongation Factor 2 Kinase - metabolism</subject><subject>Esophagus</subject><subject>eukaryotic elongation factor 2</subject><subject>Gastric cancer</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene Knockdown Techniques</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immunoglobulin G - immunology</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Lung cancer</subject><subject>Lymphoma</subject><subject>Mass spectrometry</subject><subject>MCF-7 Cells</subject><subject>Neoplasms - genetics</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Oncology, Experimental</subject><subject>Pancreatic cancer</subject><subject>Physiological aspects</subject><subject>Prostate</subject><subject>Proteins</subject><subject>Scientific imaging</subject><subject>Sequence Analysis, DNA</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>tumor associated antigen</subject><issn>1019-6439</issn><issn>1791-2423</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkk1rGzEQhpfS0ny0x16LoNCe1tXXrrSXQghJWgj0kp7FWDtry-xKrqQ1zb-vjFNjQ9FBw8wzL5rRW1UfGF0I3fGvbhMWnDK54ILpV9UlUx2rueTidYkp6-pWiu6iukppQylvGsreVhdcNrprG35Z5ac1khzBpxGyC57gGPzqEA5gc4gE7-45cYkA8WGHI8nzFGINKQXrIGNPwGe3Qk9KNeKfbcSUStZ5soPowpxIft5iImEgFrzFmN5VbwYYE75_ua-rX_d3T7ff68efDz9ubx5r2zKWa973rdK6bWzXSmCNVsIqZRtcSo1aKY0wAF_2VDDZ0pKgFKChlqoBlO56cV19O-hu5-WEvUVfJh3NNroJ4rMJ4Mx5xbu1WYWdkZSrjusi8OlFIIbfM6ZsNmGOvrzZsE5wwTuhT6gVjGicH0IRs5NL1txIVnbeKsoLtfgPVU6Pk7PB4-BK_qzh80nDGmHM6xTGef836RysD6CNIaWIw3FCRs3eJKaYxOxNYvYmKfzH07Uc6X-uKMCXA5C24HvXh3RkilItZU2buuycib9yScTL</recordid><startdate>20140501</startdate><enddate>20140501</enddate><creator>OJI, YUSUKE</creator><creator>TATSUMI, NAOYA</creator><creator>FUKUDA, MARI</creator><creator>NAKATSUKA, SHIN-ICHI</creator><creator>AOYAGI, SAYAKA</creator><creator>HIRATA, ERIKA</creator><creator>NANCHI, ISAMU</creator><creator>FUJIKI, FUMIHIRO</creator><creator>NAKAJIMA, HIROKO</creator><creator>YAMAMOTO, YUMIKO</creator><creator>SHIBATA, SYOHEI</creator><creator>NAKAMURA, MICHIYO</creator><creator>HASEGAWA, KANA</creator><creator>TAKAGI, SAYAKA</creator><creator>FUKUDA, IKUYO</creator><creator>HOSHIKAWA, TOMOKO</creator><creator>MURAKAMI, YUI</creator><creator>MORI, MASAHIDE</creator><creator>INOUE, MASAYOSHI</creator><creator>NAKA, TETSUJI</creator><creator>TOMONAGA, TAKESHI</creator><creator>SHIMIZU, YOSHIFUMI</creator><creator>NAKAGAWA, MASASHI</creator><creator>HASEGAWA, JUNICHI</creator><creator>NEZU, RIICHIRO</creator><creator>INOHARA, HIDENORI</creator><creator>IZUMOTO, SHUICHI</creator><creator>NONOMURA, NORIO</creator><creator>YOSHIMINE, TOSHIKI</creator><creator>OKUMURA, MEINOSHIN</creator><creator>MORII, EIICHI</creator><creator>MAEDA, HAJIME</creator><creator>NISHIDA, SUMIYUKI</creator><creator>HOSEN, NAOKI</creator><creator>TSUBOI, AKIHIRO</creator><creator>OKA, YOSHIHIRO</creator><creator>SUGIYAMA, HARUO</creator><general>D.A. Spandidos</general><general>Spandidos Publications</general><general>Spandidos Publications UK Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20140501</creationdate><title>The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers</title><author>OJI, YUSUKE ; TATSUMI, NAOYA ; FUKUDA, MARI ; NAKATSUKA, SHIN-ICHI ; AOYAGI, SAYAKA ; HIRATA, ERIKA ; NANCHI, ISAMU ; FUJIKI, FUMIHIRO ; NAKAJIMA, HIROKO ; YAMAMOTO, YUMIKO ; SHIBATA, SYOHEI ; NAKAMURA, MICHIYO ; HASEGAWA, KANA ; TAKAGI, SAYAKA ; FUKUDA, IKUYO ; HOSHIKAWA, TOMOKO ; MURAKAMI, YUI ; MORI, MASAHIDE ; INOUE, MASAYOSHI ; NAKA, TETSUJI ; TOMONAGA, TAKESHI ; SHIMIZU, YOSHIFUMI ; NAKAGAWA, MASASHI ; HASEGAWA, JUNICHI ; NEZU, RIICHIRO ; INOHARA, HIDENORI ; IZUMOTO, SHUICHI ; NONOMURA, NORIO ; YOSHIMINE, TOSHIKI ; OKUMURA, MEINOSHIN ; MORII, EIICHI ; MAEDA, HAJIME ; NISHIDA, SUMIYUKI ; HOSEN, NAOKI ; TSUBOI, AKIHIRO ; OKA, YOSHIHIRO ; SUGIYAMA, HARUO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c611t-2dd678865c964a15873c77c5eb48e8778eafa2bd03146087700aa50c07fa789d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Analysis</topic><topic>Antigens</topic><topic>Antigens, Neoplasm - genetics</topic><topic>Antigens, Neoplasm - metabolism</topic><topic>autoantibody</topic><topic>Breast cancer</topic><topic>Cancer</topic><topic>cancer immunotherapy</topic><topic>Cancer therapies</topic><topic>Cell cycle</topic><topic>Cell growth</topic><topic>Cell Line, Tumor</topic><topic>cytotoxic T lymphocyte</topic><topic>Elongation Factor 2 Kinase - genetics</topic><topic>Elongation Factor 2 Kinase - metabolism</topic><topic>Esophagus</topic><topic>eukaryotic elongation factor 2</topic><topic>Gastric cancer</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene Knockdown Techniques</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immunoglobulin G - immunology</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Lung cancer</topic><topic>Lymphoma</topic><topic>Mass spectrometry</topic><topic>MCF-7 Cells</topic><topic>Neoplasms - genetics</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Oncology, Experimental</topic><topic>Pancreatic cancer</topic><topic>Physiological aspects</topic><topic>Prostate</topic><topic>Proteins</topic><topic>Scientific imaging</topic><topic>Sequence Analysis, DNA</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>tumor associated antigen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OJI, YUSUKE</creatorcontrib><creatorcontrib>TATSUMI, NAOYA</creatorcontrib><creatorcontrib>FUKUDA, MARI</creatorcontrib><creatorcontrib>NAKATSUKA, SHIN-ICHI</creatorcontrib><creatorcontrib>AOYAGI, SAYAKA</creatorcontrib><creatorcontrib>HIRATA, ERIKA</creatorcontrib><creatorcontrib>NANCHI, ISAMU</creatorcontrib><creatorcontrib>FUJIKI, FUMIHIRO</creatorcontrib><creatorcontrib>NAKAJIMA, HIROKO</creatorcontrib><creatorcontrib>YAMAMOTO, YUMIKO</creatorcontrib><creatorcontrib>SHIBATA, SYOHEI</creatorcontrib><creatorcontrib>NAKAMURA, MICHIYO</creatorcontrib><creatorcontrib>HASEGAWA, KANA</creatorcontrib><creatorcontrib>TAKAGI, SAYAKA</creatorcontrib><creatorcontrib>FUKUDA, IKUYO</creatorcontrib><creatorcontrib>HOSHIKAWA, TOMOKO</creatorcontrib><creatorcontrib>MURAKAMI, YUI</creatorcontrib><creatorcontrib>MORI, MASAHIDE</creatorcontrib><creatorcontrib>INOUE, MASAYOSHI</creatorcontrib><creatorcontrib>NAKA, TETSUJI</creatorcontrib><creatorcontrib>TOMONAGA, TAKESHI</creatorcontrib><creatorcontrib>SHIMIZU, YOSHIFUMI</creatorcontrib><creatorcontrib>NAKAGAWA, MASASHI</creatorcontrib><creatorcontrib>HASEGAWA, JUNICHI</creatorcontrib><creatorcontrib>NEZU, RIICHIRO</creatorcontrib><creatorcontrib>INOHARA, HIDENORI</creatorcontrib><creatorcontrib>IZUMOTO, SHUICHI</creatorcontrib><creatorcontrib>NONOMURA, NORIO</creatorcontrib><creatorcontrib>YOSHIMINE, TOSHIKI</creatorcontrib><creatorcontrib>OKUMURA, MEINOSHIN</creatorcontrib><creatorcontrib>MORII, EIICHI</creatorcontrib><creatorcontrib>MAEDA, HAJIME</creatorcontrib><creatorcontrib>NISHIDA, SUMIYUKI</creatorcontrib><creatorcontrib>HOSEN, NAOKI</creatorcontrib><creatorcontrib>TSUBOI, AKIHIRO</creatorcontrib><creatorcontrib>OKA, YOSHIHIRO</creatorcontrib><creatorcontrib>SUGIYAMA, HARUO</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OJI, YUSUKE</au><au>TATSUMI, NAOYA</au><au>FUKUDA, MARI</au><au>NAKATSUKA, SHIN-ICHI</au><au>AOYAGI, SAYAKA</au><au>HIRATA, ERIKA</au><au>NANCHI, ISAMU</au><au>FUJIKI, FUMIHIRO</au><au>NAKAJIMA, HIROKO</au><au>YAMAMOTO, YUMIKO</au><au>SHIBATA, SYOHEI</au><au>NAKAMURA, MICHIYO</au><au>HASEGAWA, KANA</au><au>TAKAGI, SAYAKA</au><au>FUKUDA, IKUYO</au><au>HOSHIKAWA, TOMOKO</au><au>MURAKAMI, YUI</au><au>MORI, MASAHIDE</au><au>INOUE, MASAYOSHI</au><au>NAKA, TETSUJI</au><au>TOMONAGA, TAKESHI</au><au>SHIMIZU, YOSHIFUMI</au><au>NAKAGAWA, MASASHI</au><au>HASEGAWA, JUNICHI</au><au>NEZU, RIICHIRO</au><au>INOHARA, HIDENORI</au><au>IZUMOTO, SHUICHI</au><au>NONOMURA, NORIO</au><au>YOSHIMINE, TOSHIKI</au><au>OKUMURA, MEINOSHIN</au><au>MORII, EIICHI</au><au>MAEDA, HAJIME</au><au>NISHIDA, SUMIYUKI</au><au>HOSEN, NAOKI</au><au>TSUBOI, AKIHIRO</au><au>OKA, YOSHIHIRO</au><au>SUGIYAMA, HARUO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers</atitle><jtitle>International journal of oncology</jtitle><addtitle>Int J Oncol</addtitle><date>2014-05-01</date><risdate>2014</risdate><volume>44</volume><issue>5</issue><spage>1461</spage><epage>1469</epage><pages>1461-1469</pages><issn>1019-6439</issn><eissn>1791-2423</eissn><abstract>Recent studies have shown that cancer immunotherapy could be a promising therapeutic approach for the treatment of cancer. In the present study, to identify novel tumor-associated antigens (TAAs), the proteins expressed in a panel of cancer cells were serologically screened by immunoblot analysis and the eukaryotic elongation factor 2 (eEF2) was identified as an antigen that was recognized by IgG autoantibody in sera from a group of patients with head and neck squamous cell carcinoma (HNSCC) or colon cancer. Enzyme-linked immunosorbent assay showed that serum eEF2 IgG Ab levels were significantly higher in colorectal and gastric cancer patients compared to healthy individuals. Immunohistochemistry experiments showed that the eEF2 protein was overexpressed in the majority of lung, esophageal, pancreatic, breast and prostate cancers, HNSCC, glioblastoma multiforme and non-Hodgkin's lymphoma (NHL). Knockdown of eEF2 by short hairpin RNA (shRNA) significantly inhibited the growth in four eEF2-expressing cell lines, PC14 lung cancer, PCI6 pancreatic cancer, HT1080 fibrosarcoma and A172 glioblastoma cells, but not in eEF2-undetectable MCF7 cells. Furthermore, eEF2-derived 9-mer peptides, EF786 (eEF2 786-794 aa) and EF292 (eEF2 292-300 aa), elicited cytotoxic T lymphocyte (CTL) responses in peripheral blood mononuclear cells (PBMCs) from an HLA-A*24:02- and an HLA-A*02:01-positive healthy donor, respectively, in an HLA-A-restricted manner. These results indicated that the eEF2 gene is overexpressed in the majority of several types of cancers and plays an oncogenic role in cancer cell growth. Moreover, the eEF2 gene product is immunogenic and a promising target molecule of cancer immunotherapy for several types of cancers.</abstract><cop>Greece</cop><pub>D.A. Spandidos</pub><pmid>24589652</pmid><doi>10.3892/ijo.2014.2318</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1019-6439 |
| ispartof | International journal of oncology, 2014-05, Vol.44 (5), p.1461-1469 |
| issn | 1019-6439 1791-2423 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4027928 |
| source | Spandidos Publications Journals; MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Analysis Antigens Antigens, Neoplasm - genetics Antigens, Neoplasm - metabolism autoantibody Breast cancer Cancer cancer immunotherapy Cancer therapies Cell cycle Cell growth Cell Line, Tumor cytotoxic T lymphocyte Elongation Factor 2 Kinase - genetics Elongation Factor 2 Kinase - metabolism Esophagus eukaryotic elongation factor 2 Gastric cancer Gene Expression Regulation, Neoplastic Gene Knockdown Techniques Genetic aspects Health aspects Humans Immunoglobulin G - immunology Immunoglobulins Immunotherapy Leukemia Lung cancer Lymphoma Mass spectrometry MCF-7 Cells Neoplasms - genetics Neoplasms - immunology Neoplasms - pathology Oncology, Experimental Pancreatic cancer Physiological aspects Prostate Proteins Scientific imaging Sequence Analysis, DNA T-Lymphocytes, Cytotoxic - immunology tumor associated antigen |
| title | The translation elongation factor eEF2 is a novel tumor-associated antigen overexpressed in various types of cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T07%3A34%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20translation%20elongation%20factor%20eEF2%20is%20a%20novel%20tumor-associated%20antigen%20overexpressed%20in%20various%20types%20of%20cancers&rft.jtitle=International%20journal%20of%20oncology&rft.au=OJI,%20YUSUKE&rft.date=2014-05-01&rft.volume=44&rft.issue=5&rft.spage=1461&rft.epage=1469&rft.pages=1461-1469&rft.issn=1019-6439&rft.eissn=1791-2423&rft_id=info:doi/10.3892/ijo.2014.2318&rft_dat=%3Cgale_pubme%3EA412556702%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1932329388&rft_id=info:pmid/24589652&rft_galeid=A412556702&rfr_iscdi=true |